NCT05849298 2026-04-13
PSMACare
Novartis
Phase 2 Active not recruiting
Clinical Trials
7 trialsNCT06894511 2026-04-08
PSMAndARPI
Novartis
Phase 2 Active not recruiting
NCT07047118 2026-04-08
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis
Phase 2 Active not recruiting
NCT05114746 2026-04-01
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan
Novartis
Phase 2 Active not recruiting
NCT04663997 2026-03-27
177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT06964958 2026-02-24
LASER
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04343885 2025-07-11
UpFrontPSMA
Peter MacCallum Cancer Centre, Australia
Phase 2 Active not recruiting